SG10201805177PA - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents
Use of ferric citrate in the treatment of chronic kidney disease patientsInfo
- Publication number
- SG10201805177PA SG10201805177PA SG10201805177PA SG10201805177PA SG10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA SG 10201805177P A SG10201805177P A SG 10201805177PA
- Authority
- SG
- Singapore
- Prior art keywords
- increase
- iron
- kidney disease
- chronic kidney
- disease patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| US201361800618P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201805177PA true SG10201805177PA (en) | 2018-07-30 |
Family
ID=49769729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
| SG10201805177PA SG10201805177PA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408521WA SG11201408521WA (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20130345303A1 (enExample) |
| EP (3) | EP4335436A3 (enExample) |
| JP (4) | JP2015535209A (enExample) |
| KR (2) | KR102150135B1 (enExample) |
| CN (2) | CN113244209A (enExample) |
| AU (2) | AU2013278000A1 (enExample) |
| BR (1) | BR112014032049A2 (enExample) |
| CA (1) | CA2876982A1 (enExample) |
| DK (1) | DK3730136T3 (enExample) |
| EA (1) | EA201590062A1 (enExample) |
| ES (2) | ES2970050T3 (enExample) |
| HK (1) | HK1214503A1 (enExample) |
| IL (1) | IL236356A0 (enExample) |
| MX (1) | MX2014015615A (enExample) |
| NO (1) | NO2025048I1 (enExample) |
| PL (1) | PL3730136T3 (enExample) |
| SG (2) | SG11201408521WA (enExample) |
| WO (1) | WO2013192565A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010276242B2 (en) | 2009-07-21 | 2014-05-29 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| DK3287133T3 (da) | 2013-06-05 | 2019-07-01 | Tricida Inc | Proton-bindende polymerer til oral indgivelse |
| EP2856941B1 (en) * | 2013-10-01 | 2020-11-25 | Fresenius Medical Care Deutschland GmbH | Method and apparatuses for determining a patient's daily loss of iron |
| EP3747432A1 (en) * | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| KR102625115B1 (ko) | 2014-12-10 | 2024-01-12 | 트리시다, 인크. | 경구 투여용 양성자-결합 폴리머 |
| BR112017018963A2 (pt) * | 2015-03-04 | 2018-05-15 | Keryx Biopharmaceuticals Inc | método para tratar anemia por deficiência de ferro |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| KR102655774B1 (ko) | 2016-05-06 | 2024-04-05 | 트리시다, 인크. | 산-염기 장애의 치료를 위한 조성물 및 방법 |
| JP7387435B2 (ja) | 2017-09-19 | 2023-11-28 | 日本たばこ産業株式会社 | 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用 |
| IL319146A (en) | 2017-11-03 | 2025-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| CA3117071A1 (en) | 2018-10-29 | 2020-05-07 | Pharmacosmos Holding A/S | Treating iron deficiency with ferric carboxymaltose |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0922461A4 (en) * | 1996-07-19 | 2002-07-17 | Nikken Chemicals Co Ltd | MEDICINE AGAINST HYPERPHOSPHATANEMIA |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| MX2008002360A (es) | 2005-08-18 | 2008-04-29 | Globoasia Llc | Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. |
| AU2007205167B2 (en) * | 2006-01-06 | 2013-06-13 | Vifor (International) Ag | Methods and compositions for administration of iron |
| CN101374416A (zh) | 2006-01-30 | 2009-02-25 | 环亚有限公司 | 逆转、防止、延迟或稳定软组织钙化的方法 |
| AU2010276242B2 (en) | 2009-07-21 | 2014-05-29 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
-
2013
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en not_active Withdrawn
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en not_active Ceased
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 HK HK16102352.0A patent/HK1214503A1/zh unknown
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active Active
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active Ceased
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
-
2025
- 2025-11-06 NO NO2025048C patent/NO2025048I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201805177PA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| HK1223031A1 (zh) | 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 | |
| JO2828B1 (en) | Anti-Hepsidine antibodies and their uses | |
| WO2009125300A3 (en) | Oxygenation procedures for newborns and devices for use therein | |
| EA201071421A1 (ru) | Анти-flt3 антитела | |
| SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
| MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| MX2014011186A (es) | Metodo para mejorar la eficiencia de las transfusiones de sangre. | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| BRPI0912912A2 (pt) | proteína de fusão, método para tratar um indivíduo que tem um tumor, método para inibir a angiogênese em um indivíduo, método para tratar um indivíduo que tem câncer de ovário, método para tratar um indivíduo que tem distúrbio metabólico, uso da proteína de fusão, método para inibir linfangiogênese fisiológica ou linfangiogênese patológica em um indivíduo, método para inibir metástase tumoral em um indivíduo, método para inibir o crescimento de um tumor secundário em um indivíduo, método para inibir a cooptação de um vaso sanguíneo por um tumor em um indivíduo, método para tratar câncer de mama de um indivíduo | |
| HK1204578A1 (en) | Medicament for the treatment of acute myeloid leukemia (aml) | |
| MX357941B (es) | Serpinas modificadas para el tratamiento de trastornos de la coagulacion. | |
| EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
| WO2010102216A3 (en) | Enhancing coagulation or reducing fibrinolysis | |
| WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
| MX2014002762A (es) | Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico. | |
| WO2012075244A3 (en) | Use of hemoglobin effectors to increase the bioavailability of therapeutic gases | |
| MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
| BR112014009414A2 (pt) | uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos | |
| HK1218883A1 (zh) | 对神经毒剂的暴露的治疗 | |
| BR112015028252A2 (pt) | método de tratamento de câncer de pulmão por vacinação com lipopeptídeo muc-1 |